Stoke Therapeutics (STOK) Change in Receivables (2024 - 2026)
Stoke Therapeutics' quarterly Change in Receivables came in at -$1.5 million in Q1 2026, down 212.15% year-on-year from $1.3 million in Q1 2025, and up 55.13% quarter-over-quarter from -$3.3 million in Q4 2025.
Stoke Therapeutics has reported Change in Receivables for 3 years, with the latest figure at -$1.5 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Receivables fell 212.15% year-over-year to -$1.5 million; the trailing twelve-month figure through Mar 2026 stood at -$3.8 million (changed N/A YoY), and the FY2025 full-year result was $4.3 million, up 8436.0% from the prior year.
- Change in Receivables for Q1 2026 stood at -$1.5 million, up from -$3.3 million in the prior quarter.
- The five-year high for Change in Receivables was $1.3 million in Q1 2025, with the low at -$3.3 million in Q4 2025.
- Average Change in Receivables over 3 years is -$942750.0, with a median of -$892000.0 recorded in 2024.
- Year-over-year, Change in Receivables tumbled 1011.41% in 2025 and tumbled 212.15% in 2026.
- Tracing STOK's Change in Receivables over 3 years: stood at -$298000.0 in 2024, then plunged by 1011.41% to -$3.3 million in 2025, then soared by 55.13% to -$1.5 million in 2026.
- The last three Change in Receivables figures came in at -$1.5 million (Q1 2026), -$3.3 million (Q4 2025), and $1.3 million (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 208,524.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -39.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -1.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 110.42 Mn |
| 10 | Stoke Therapeutics | 1.92 Bn | 1.92 Bn | - | -1.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.49 Mn |
| Mar 31, 2026 | -1.49 Mn |
| Dec 31, 2025 | -3.31 Mn |
| Dec 31, 2025 | -3.31 Mn |
| Mar 31, 2025 | 1.33 Mn |
| Mar 31, 2025 | 1.33 Mn |
| Dec 31, 2024 | -298,000.00 |
| Dec 31, 2024 | -298,000.00 |